Taragarestrant (meglumine)

Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD) . Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2].

Product Specifications

CAS Number

[2446618-18-2]

Product Name Alternative

D-0502 (meglumine)

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/taragarestrant-meglumine.html

Purity

99.33

Solubility

DMSO : 20.83 mg/mL (ultrasonic)

Smiles

CC(C)(F)CN1[C@@](C2=C(C=C(C=C2Cl)/C=C/C(O)=O)Cl)([H])C3=C(C[C@H]1C)C4=CC=CC=C4N3.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC

Molecular Formula

C32H42Cl2FN3O7

Molecular Weight

670.60

References & Citations

[1]Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78 (13) :5776.|[2]WHO Drug Information. International Nonproprietary Names for Pharmaceutical.